SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
Phase 2
Completed
- Conditions
- InfluenzaSwine-origin A/H1N1 Influenza
- Interventions
- Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 450
- Registration Number
- NCT00954798
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
Phase 2
Completed
- Conditions
- InfluenzaSwine-origin A/H1N1 Influenza
- Interventions
- Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)Biological: Normal saline solution (placebo)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 849
- Registration Number
- NCT00953524
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
Phase 2
Completed
- Conditions
- InfluenzaSwine-origin A/H1N1 Influenza
- Interventions
- Biological: Monovalent Subvirion A/H1N1 Influenza vaccineBiological: Normal saline solution (placebo)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 474
- Registration Number
- NCT00952419
Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults
Phase 2
Completed
- Conditions
- Rabies
- Interventions
- Biological: Purified Vero Rabies Vaccine - Serum FreeBiological: Purified inactivated rabies vaccine
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 384
- Registration Number
- NCT00948272
Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine 2009-2010 formulation
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 131
- Registration Number
- NCT00945438
Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus (split virion, inactivated) vaccine
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 130
- Registration Number
- NCT00946179
Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Biological: REPEVAXBiological: Monovalent Tetanus vaccine
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 52
- Registration Number
- NCT00928785
- Locations
- 🇫🇷
Hôpital Gabriel Montpied - CHU Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷Hôpital Bichat Claude Bernard, Paris, France
🇫🇷Groupe Hospitalier Cochin - Saint-Vincent de Paul, Paris, France
Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly
Phase 2
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 225
- Registration Number
- NCT00885157
Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 242
- Registration Number
- NCT00885105
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae InfectionsOrthomyxovirus Infections
- Interventions
- Biological: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 350
- Registration Number
- NCT00884182
© Copyright 2025. All Rights Reserved by MedPath